177lu-psma-617
novartis
[' vision', 'vision trial']
esmo 2022: radiographic progression-free survival correlation with time-to-event endpoints: a post hoc analysis of the vision trial - mashupmd 
Business & Finance News Business & Finance News News Political News US & World News Medicine & Surgery.